Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Personalized Medicine Opportunity

This article was originally published in Start Up

Executive Summary

Personalized medicine is a field as vast as the differences between individuals, and encompasses technologies, markets, and treatment strategies ranging from autologous cancer vaccines to molecular diagnostics and gene-targeted drugs to methods for visualizing subtle differences in tissues--the foci of the three companies profiled herein.

You may also be interested in...



Xanthus Life Sciences Inc.

Xanthus is pursuing personalized medicine in a way quite different from pharmacogenomics players: rather than exclude patients from treatment, this start-up aims to optimize drug dosing for everyone--beginning with anti-cancer compounds. Instead of relying on genes that may or may not be activated, Xanthus is gauging phenotypic factors, traits that are already physically manifest.

Aureon Biosciences

The importance of tissue analysis in diagnosing and characterizing disease, notably cancer, can't be underestimated. But analysis of tissue as a source of predictive medical information has been slow to evolve. Aureon Biosciences is changing this situation by developing a new tissue analysis platform to create predictive tests that oncologists can use to guide selection of cancer treatments.

Favrille Inc.

Favrille Inc. believes that it has found a way to significantly curtail cycle time for vaccine production, putting it in position to implement a workable business model for patient-specific therapies for lymphoma and diseases of the immune system.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC090772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel